

Frequent Epigenetic Inactivation of *RASSF1A* by Aberrant Promoter Hypermethylation in Human Gastric Adenocarcinoma¹

Do-Sun Byun, Min-Goo Lee, Kwon-Seok Chae, Byung-Gyu Ryu, and Sung-Gil Chi²

Department of Pathology, School of Medicine, Kyung Hee University, Seoul 130-701, Korea

Abstract

Methylation associated inactivation of *RASSF1*, a putative tumor suppressor identified at 3p21.3, has been frequently observed in several human malignancies, including lung and breast cancers. To explore the penetrance of *RASSF1* in gastric carcinogenesis, we performed expression and mutation analyses of 3 isoforms of *RASSF1* (A, B, and C) in 150 gastric specimens, including 15 carcinoma cell lines. *RASSF1A* and *RASSF1B* transcripts were not expressed in 60% (9 of 15) and 33% (5 of 15) of gastric carcinoma cell lines, respectively, whereas *RASSF1C* was detectable in all cell lines. Bisulfite DNA sequencing analysis revealed that the CpG island in the *RASSF1A* promoter is hypermethylated in all *RASSF1A*-nonexpressing cell lines. In addition, both *RASSF1A* and *RASSF1B* were re-expressed by treatment with the demethylating agent 5-aza-2'-deoxycytidine. Among 90 primary gastric adenocarcinomas examined, 41 (46%) and 19 (21%) expressed no or abnormally low levels of *RASSF1A* and *RASSF1B*, respectively, and 12 (13%) tumors showed no expression of both isoforms. Loss or abnormal down-regulation of *RASSF1A* correlated with tumor stage and grade but not with histological types of tumors. Methylation-specific PCR analysis demonstrated that 95% (39 of 41) of *RASSF1A*-nonexpressing primary tumors are methylated at the CpG sites in the promoter, whereas none of the adjacent noncancerous or normal tissues are methylated. No somatic mutations were detected in *RASSF1* transcripts expressed in unmethylated tumors. However, 10 methylated tumors, including 4 cell lines, showed low genomic levels of *RASSF1* and expressed no *RASSF1A* transcripts, suggesting that *RASSF1A* inactivation might be caused by both epigenetic and genetic mechanisms in a subset of gastric adenocarcinomas. In conclusion, our data indicate that epigenetic transcriptional silencing of *RASSF1*, especially *RASSF1A* isoform, is a frequent event in gastric tumorigenesis and might play an important role in the malignant progression of gastric adenocarcinomas.

Introduction

Gastric adenocarcinoma is one of the most commonly diagnosed malignancies worldwide and a leading cause of cancer mortality in certain areas such as Korea, Japan, South America, and Eastern Europe (1). Although evidence has accumulated indicating the involvement of the alterations of multiple genes such as *p53*, *K-ras*, *c-erbB2*, *K-sam*, and *E-Cadherin*, the underlying molecular events that drive the neoplastic process in gastric cancer are largely undefined (2). LOH³ is one of the most frequent genetic alterations in solid tumors, and the characterization of chromosomal regions with a high rate of LOH leads to the identification of putative tumor suppressor genes. Previous cytogenetic and LOH studies of gastric adenocarci-

nomas have shown the significant allelic loss on several chromosomal arms, including 3p, 4p, 5q, 12q, 17p, and 18q (3–5).

The short arm of chromosome 3 is one of the most frequently deleted regions in gastric cancers, and many gastric cancer cell lines have homozygous deletions of 3p (4, 6). Recent allelotyping analyses detected deletion of 3p in 25–81% of gastric adenocarcinomas, and several genomic regions, including 3p14, 3p21, and 3p25–26, were revealed to undergo frequent allelic loss in gastric cancers, suggesting the presence of multiple candidate tumor suppressor gene(s) on 3p (4, 5). Loss of expression or mutational alterations of *fragile histidine triad* and *von Hippel-Lindau*, which are known to reside at 3p14 and 3p25–26, respectively, have been observed in many gastric cancers, implicating a role in gastric tumorigenesis (7, 8).

Recently, *RASSF1* was suggested as the major target tumor suppressor at 3p21.3 based on its frequent epigenetic silencing and LOH in lung cancers (9). *RASSF1* encodes more than seven isoforms, including *RASSF1A*, *RASSF1B*, and *RASSF1C*, which are derived from alternative mRNA splicing and promoter usage. Transcriptional silencing of *RASSF1A* was observed in a considerable proportion of lung, breast, ovarian, and nasopharyngeal cancers by *de novo* methylation at the CpG island in the promoter (10–13). In small cell lung cancers, allelic loss of 3p21.3 was associated with *RASSF1A* methylation, suggesting that both genetic and epigenetic mechanisms are implicated in *RASSF1A* inactivation in some tumor types (11).

The three major isoforms of *RASSF1* have four common exons (exons 3–6), which encode a Ras association domain (14). *RASSF1A* has two 5' exons (1 α and 2 $\alpha\beta$) and encodes a 39 kDa peptide (9). *RASSF1A* contains an NH₂-terminal cysteine-rich diacylglycerol/phorbol ester binding domain, and its COOH terminus shows high homology to Ras effector Nore1/Maxp1 (15). *RASSF1B* contains exons 1 β and 2 $\alpha\beta$ and most likely encodes only the Ras association domain. Transcription of *RASSF1C* initiates in exon 2 γ , and its protein product lacks similarity to Nore1 or any other known protein. In addition to containing the predicted Ras association domain, *RASSF1A* and *RASSF1C* have PEST sequences, and a serine residue within this region was identified as a putative phosphorylation target *in vitro* for ataxia-telangiectasia-mutated (16).

It is well documented that Ras proteins bind a diverse array of effector molecules and mediate tumor suppressive effects, such as terminal differentiation and apoptosis, as well as oncogenic effects (17, 18). Recent studies demonstrated that exogenous expression of *RASSF1A* decreases *in vitro* colony formation, suppresses anchorage-independent growth, and dramatically reduces tumorigenicity *in vivo* (9, 10). In this context, *RASSF1A* may play a role as an effector molecule in the Ras-activated growth inhibition signaling pathways. It was also hypothesized that *RASSF1* inactivation may shift the balance of Ras activities toward a growth-promoting effect and thus be a tumorigenic mechanism that is distinct from the oncogenic activation of Ras signaling in tumors (10, 19). Interestingly, loss of *RASSF1C* has been detected in six of nine ovarian cell lines, and *RASSF1C* protein was found to bind Ras in a GTP-dependent manner both *in vitro* and *in vivo* and mediate the apoptotic effects of oncogenic Ras,

Received 6/22/01; accepted 8/15/01.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported by a grant from Korea Science and Engineering Foundation (2000).

² To whom requests for reprints should be addressed, at Department of Pathology, College of Medicine, Kyung Hee University, 130-701 Seoul, Republic of Korea. Phone: (82) (2) 961-0920; Fax: (82) (2) 961-0302; E-mail: sgchi@khu.ac.kr.

³ The abbreviations used are: LOH, loss of heterozygosity; RT-PCR, reverse transcription-PCR; SSCP, single-strand conformation polymorphism; *GAPDH*, glyceraldehyde-3-phosphate dehydrogenase.

suggesting that *RASSF1* isoforms might have tissue-specific roles (19).

In the present study, we investigated the expression and mutation status of *RASSF1* located at 3p21.3 in a series of primary gastric adenocarcinomas and cell lines to explore the candidacy of *RASSF1* as a suppressor in gastric carcinogenesis. Our data demonstrate that *RASSF1A* and *RASSF1B* expression is lost or down-regulated in a majority of gastric cell lines and primary tumors by aberrant promoter hypermethylation. Moreover, altered expression of *RASSF1A* correlated with tumor stage and grade, suggesting that inactivation of *RASSF1A* may play a critical role in the malignant progression of gastric cancers.

Materials and Methods

Tissue Specimens and Human Cell Lines. Total 135 gastric tissues, including 90 primary adenocarcinomas and 15 normal gastric tissues, were obtained from 90 gastric cancer patients and 15 noncancer patients by surgical resection in the Kyung Hee University Medical Center (Seoul, Korea). Tissue specimens were snap-frozen in liquid N₂ and stored at -70°C until used. Fifteen human gastric cancer cell lines (SNU1, SNU5, SNU16, SNU216, SNU484, SNU601, SNU620, SNU638, SNU719, MKN1, MKN28, MKN45, MKN74, AGS, and KATO-III) were obtained from Korea Cell Line Bank (Seoul National University, Seoul, Korea) or American Type Culture Collection (Rockville, MD). Extraction of total cellular RNA and synthesis of cDNA were performed as described previously (20). Genomic DNA was extracted from the same cells of the tissues from the DNA phase after RNA was extracted.

Quantitative PCR Analysis. Our PCR-based strategies used for quantitative analysis of expression and genomic levels of *RASSF1* were described previously (21). Briefly, 1:4 diluted cDNA (12.5 ng/50 μl PCR reaction) undergoing 24–36 cycles was observed to be within the logarithmic phase of amplification and yielded reproducible results with primers RSF-3 (sense; 5'-TCTGGGCGTCGTGCGCAA-3') and RSF-4 (antisense; 5'-GAACCTTGATGAAGCCTGTG-3') for *RASSF1A*, 1B (sense; 5'-CGGTTTCCAGACGCCAGGT-3') and RSF-4 (antisense; see above) for *RASSF1B*, 1C (sense; 5'-GGAGGCGCCTTCTTTCGAAA-3') and RSF-4 (antisense; see above) for *RASSF1C*, and an endogenous expression standard gene *GAPDH* (22, 23). PCR was done for 34 cycles at 95°C (1 min), 58°C–62°C (0.5 min), and 72°C (1 min) in 1.5 mM MgCl₂-containing reaction buffer (PCR buffer II; Perkin-Elmer). RT-PCR products (10 μl) were resolved on 2% agarose gels. Quantitation of *RASSF1* expression levels was achieved by densitometric scanning of the ethidium bromide-stained gels. Absolute area integrations of the curves representing each specimen were then compared after adjustment for *GAPDH* expression. For genomic PCR analysis, 200 ng of genomic DNA were used for amplification of the exon 3 region of *RASSF1* with intron-specific primers RF3S (sense; 5'-ATGTATATGTACATCAGGA-3') and RF3AS (antisense; 5'-CAGGCACATAGCTGGGTACC-3'). Integration and analysis were performed using Molecular Analyst software program (Bio-Rad, Hercules, CA).

5-aza-2'-deoxycytidine Treatment. To assess reactivation of *RASSF1* expression, 15 gastric cancer cell lines were plated in six-well tissue plates 24 h before treatment. 5-aza-2'-deoxycytidine (Sigma Chemical Co., St. Louis, MO) was added to the fresh medium at concentrations of 5 μM in duplicate, and cells were harvested after 4 days.

Bisulfite DNA Sequencing. Genomic DNA (1 μg) in a volume of 50 μl was denatured by NaOH (final concentration 0.3 M). Hydroquinone (30 μl of 10 mM) and 520 μl of 3 M sodium bisulfite (pH 5.0) were added and incubated at 55°C for 16–20 h. DNA samples were purified using Wizard DNA clean-up system (Promega Corp., Madison, WI), again treated with NaOH at 37°C for 15 min, precipitated with ethanol, and resuspended in distilled water. Bisulfite-modified DNA (50 ng) was subjected to PCR amplification of the CpG island in the *RASSF1A* promoter using primers PS (5'-CATTCCCTTCCAT-3') and PAS (5'-TTCTATTTACTCTATTCTATTTT-3'). The PCR products were cloned into pCR^{II} vectors (Invitrogen, Carlsbad, CA), and 10 clones of each specimen were sequenced by automated fluorescence-based DNA sequencing to determine the methylation status.

Methylation-specific PCR. PCR was performed with methylation-specific primers MS-1 (sense; 5'-TTTTTCCATTTCCGCTCTCT-3') and MS-2 (antisense; 5'-CGTTTTTGCCCTTCTTCGC-3') and unmethylation-specific primers UMS-1 (sense; 5'-TCACCCATTTTCCATTTCTCT-3') and UMS-4 (antisense; 5'-CTTTTTTCCCTTCTTCTCTT-3') using 200 ng of the bisulfite-modified genomic DNA as templates for 38 cycles at 95°C for 1 min, at 60°C–63°C for 1 min, and 72°C for 1 min. The PCR products (15 μl) were resolved on a 2% agarose gel.

Nonisotopic RT-PCR-SSCP Analysis. Nonisotopic RT-PCR-SSCP analysis was performed as described previously (20). The isoform-specific regions (1α, 1β, 2αβ, and 2γ) and exons 3–6 of *RASSF1* transcripts were amplified with 10 sets of primers. Sequences of the primers used for our PCR-SSCP analysis will be obtained on request. The PCR products (20 μl) mixed with 5 μl of 0.5 N NaOH, 10 mM EDTA, 10 μl of denaturing loading buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, and 0.05% xylene cyanol), and 15 μl of double-distilled water. After heating at 95°C for 5 min, samples were loaded in wells precooled to 4°C. SSCP was performed using 8% nondenaturing acrylamide gels containing 10% glycerol at 4°C–8°C or 18°C–22°C.

Results and Discussion

Expression Status of *RASSF1* in Normal Gastric Tissues. To elucidate the status of *RASSF1* during gastric cancer pathogenesis, we initially evaluated mRNA expression of three *RASSF1* isoforms (*A*, *B*, and *C*) in 15 normal gastric tissues obtained from noncancer patients by quantitative RT-PCR. The three *RASSF1* isoform transcripts were detected in all normal tissues analyzed (Figs. 1 and 2). Consistent with a previous report, *RASSF1B* levels were significantly low compared with *RASSF1A* and *RASSF1C*, and we used quantitative nest-PCR approach for analysis of *RASSF1B* expression (9). Quantitative PCR was repeated at least three times for each specimen, and no significant variations were observed in expression levels of the three isoforms among normal tissue specimens (*RASSF1A*, 1.19–1.45; *RASSF1B*, 0.60–0.82; *RASSF1C*, 0.98–1.38; Fig. 2).




Fig. 1. Expression and genomic status of *RASSF1* in gastric carcinoma cell lines and tissues. *A*, PCR analysis of *RASSF1* in gastric carcinoma cell lines. For expression analysis, three *RASSF1* isoform transcripts were amplified by RT-PCR using isoform-specific primers. The PCR products (10 μl) were resolved on a 2% agarose gel. For analysis of *RASSF1* gene levels, the exon 3 region of the gene was amplified using intron-specific primers using the genomic DNA isolated from the same cells used for mRNA expression analysis as templates. *GAPDH* was used as an endogenous control. *B*, RT- and genomic-PCR analyses of *RASSF1* in gastric tissues. Expression levels of *RASSF1* in cancer and adjacent noncancerous tissues (1–5) were compared using matched tissue sets obtained from the same gastric cancer patients. *N*, normal tissues; *T*, tumor tissues.




Fig. 2. Expression levels of *RASSF1* in primary gastric carcinomas. *A*, expression of three *RASSF1* isoforms (*RASSF1*/*GAPDH*) in normal and carcinoma tissues. Quantitation was achieved by densitometric scanning of *RASSF1* RT-PCR products in ethidium bromide-stained gels, and absolute area integrations of the curves representing each specimen were compared after adjustment for *GAPDH*. Quantitative PCR was repeated at least three times for each specimen, and the means were obtained. *Bar*, the mean expression level of each specimen group. *B*, comparison of *RASSF1A* and *RASSF1B* expression levels between early (*E*) and advanced (*A*) tumors. *C*, comparison of *RASSF1A* and *RASSF1B* expression levels between well differentiated (*WD*), moderately differentiated (*MD*), and poorly differentiated (*PD*) tumors.

Loss of *RASSF1* Expression in Gastric Carcinoma Cell Lines.

We next characterized the expression status of *RASSF1* in 15 gastric carcinoma cell lines. As shown in Fig. 1A, *RASSF1A* and *RASSF1B* were not expressed in nine (60%) and five (33.3%) cell lines, respectively. Whereas two cell lines (SNU5 and SNU620) showed no expression of both isoforms, seven (SNU1, SNU484, SNU601, SNU719, MKN28, MKN74, and AGS) and three (SNU216, MKN1, and MKN45) showed *RASSF1A*- and *RASSF1B*-specific loss, respectively. Thus, 80% (12 of 15) of gastric cell lines examined showed no expression of *RASSF1A* and/or *RASSF1B* mRNA. *RASSF1C* mRNA was detectable in all cells. However, four (SNU484, SNU620, SNU719, and MKN28) cell lines expressed abnormally low levels of *RASSF1C*. Interestingly, these cell lines also showed low genomic levels of the *RASSF1* gene, suggesting allelic deletion of the gene in these cell lines.

Frequent Alteration of *RASSF1* Expression in Primary Gastric Carcinomas. Next we analyzed *RASSF1* expression in 90 primary gastric carcinomas, including 30 matched sets. Expression levels of *RASSF1A*, *RASSF1B*, and *RASSF1C* were observed in the ranges of 0.02–1.47, 0.05–0.86, and 0.52–1.42, respectively, and *RASSF1A* and *RASSF1B* levels in tumors showed a significant difference compared with those in normal tissues (Figs. 1A and 2). On the basis of the *RASSF1* expression in normal gastric tissues, we arbitrarily set expression levels less than a half (*RASSF1A* < 0.67, *RASSF1B* < 0.36, and *RASSF1C* < 0.61) of normal means (*RASSF1A*, 1.34; *RASSF1B*, 0.72; and *RASSF1C*, 1.22) as abnormally low. No or abnormally low expression of *RASSF1A* and *RASSF1B* was found in 45.6% (41 of 90) and 21.1% (19 of 90) of primary carcinomas, respectively, and 13.3% (12 of 90) of tumors showed altered expression for both isoforms (Fig. 2). Thus, 53.3% (48 of 90) of primary gastric carcinomas were identified to have loss or abnormal reduction of *RASSF1A* and/or *RASSF1B*. Among 30 matched sets from the same patients, tumor-specific reduction of *RASSF1A* and *RASSF1B* was found in 22 (73.3%) and 9 (30%) cases, respectively (Fig. 1A). Additionally, loss or abnormal reduction of *RASSF1A* was significantly high in advanced tumors (30 of 48, 62.5%) compared with early stage tumors (11 of 42, 26.2%; $P < 0.0001$) and more frequent in poorly differentiated tumors (26 of 42, 61.9%) than well or moderately differentiated tumors [33.3% (3 of 9) and 30.8% (12 of 39), respectively] ($P = 0.01$). However, *RASSF1A* alteration showed no association with histological types of tumor [diffused, 44.8% (13 of 29); intestinal, 45.9% (28 of 61)]. In contrast to *RASSF1A*, loss or abnormal reduction *RASSF1B* expression showed no correlation with histopathological characteristics of tumors (Fig. 2). Expression of *RASSF1C* isoform was observed in all tumors examined, but abnormally low expression was identified in six (6.7%) tumors (Fig. 1). As for four cell lines, these tumors showed low levels of the gene in quantitative genomic PCR and also expressed no or low levels of *RASSF1A* and/or *RASSF1B*, suggesting that altered expression of *RASSF1* mRNA might be associated with allelic deletion of the gene in a subset of gastric cancers. Collectively, our results indicate that loss or abnormal reduction of *RASSF1*, especially *RASSF1A* isoform, is a frequent event in gastric tumorigenesis and may contribute to the malignant progression of human gastric cancers.

RASSF1B is expressed mainly in hematopoietic cells, whereas *RASSF1A* and *RASSF1C* are expressed ubiquitously (9). Although its levels were significantly low, we could detect *RASSF1B* expression in normal and cancerous gastric tissues. Some *RASSF1B* transcripts detected in tissue specimens might be derived from the infiltrating lymphocytes, but expression of *RASSF1B* in gastric carcinoma cell lines and its tumor-specific alteration raises the possibility that




Fig. 3. Reactivation of *RASSF1* expression by 5-aza-2'-deoxycytidine treatment. Fifteen gastric cancer cell lines and the A549 lung cancer cell line used as a control were treated with the demethylating agent, 5-aza-2'-deoxycytidine (5 μM), for 4 days, and expressions of *RASSF1A* and *RASSF1B* were evaluated by quantitative RT-PCR. C, untreated control; T, treated.

RASSF1B inactivation might be implicated in gastric carcinogenesis. It was demonstrated previously that *RASSF1C* mediates the apoptotic effects of oncogenic Ras, and expression of *RASSF1C* is lost in six of nine ovarian cell lines, suggesting that *RASSF1* isoforms might have tissue-specific roles (19). In this context, our observation of the *RASSF1B*-specific alteration in some cell lines and primary tumors suggests the possible tissue-specific role of *RASSF1B* in gastric tumorigenesis. Additional studies will be required to characterize the biological significance of *RASSF1B* inactivation in gastric tumor development.

Absence of *RASSF1* Mutations in Gastric Cancers. The 3p21 region, where the *RASSF1* gene is located, undergoes frequent allelic losses in a variety of human malignancies, including gastric cancer (4, 5, 24, 25). Recently, *RASSF1A* inactivation by two hits (allelic loss at 3p21.3 and promoter methylation) was demonstrated in small cell lung cancers (11). Although we did not perform the comprehensive LOH study for *RASSF1* locus, quantitative genomic PCR analysis revealed that 26.7% (4 of 15) of gastric cell lines and 14.6% (6 of 41) of primary tumors have low *RASSF1* gene levels (Fig. 1). These observations suggest that abnormal expression of *RASSF1* might be associated with the allelic deletion of the gene in a subset of tumors, and somatic mutations might exist in the *RASSF1* transcripts expressed from the remaining allele. For screening of *RASSF1* mutations, RT-PCR-SSCP analysis was performed for the entire coding region of three isoform transcripts. However, we failed to detect any types of mutation leading to amino acid substitutions or frameshifts except for previously described polymorphisms at codons 53 (CGC to CGT) and 56 (CCC to CCT), whereas 34.4% (31 of 90) of the same set of tumors were found to carry *p53* mutations, indicating that somatic mutation is not a main mechanism for *RASSF1* inactivation in gastric cancers (13).

Hypermethylation of the CpG Island in the *RASSF1A* Promoter. To investigate whether aberrant DNA methylation might be involved in the loss of *RASSF1A* expression, the 15 gastric cell lines

were treated with the demethylating agent 5-aza-2'-deoxycytidine. As shown in Fig. 3, *RASSF1A* and *RASSF1B* transcripts were re-expressed in all nonexpressing cell lines, including the A549 lung cancer cell line used as a control, indicating that *RASSF1A* and *RASSF1B* are transcriptionally silenced in these cells by aberrant DNA methylation, and the promoters of these two isoforms are concomitantly hypermethylated in some cancers (9). No detectable changes in *RASSF1C* expression were observed, which is consistent with the previous report showing that CpG sites in the presumed *RASSF1C* promoter region were not methylated in human cancer cell lines (9–12).

To additionally define the methylation status of the gene, we performed bisulfite DNA sequencing analysis of the CpG island in the *RASSF1A* promoter. The promoter region (nucleotide -139 to +3) spanning 15 CpG sites was amplified by PCR using sodium bisulfite-modified genomic DNA as templates, and 10 PCR clones of each specimen were sequenced (9). The 15 CpG sites analyzed were identified to be completely methylated in all *RASSF1A*-nonexpressing cell lines, whereas none of the *RASSF1A*-expressing cells showed methylation in this region (Fig. 4). Additionally, in five primary tumors examined, complete or high rate of methylation was identified in four tumors expressing no or low levels of *RASSF1A*, whereas no methylation was found in the adjacent noncancerous tissues and a *RASSF1A*-expressing tumor.

To determine the overall frequency of *RASSF1A* methylation in





Fig. 4. Methylation status of the CpG island in the *RASSF1A* promoter. The *RASSF1A* promoter region comprised of 15 CpG sites (nucleotide -139 to +3) was amplified by PCR with bisulfite-modified genomic DNA as templates. The PCR products were cloned, and 10 clones of each specimen were sequenced. The 15 CpG sites are numbered according to those listed in Ref. 9. Black, gray, and white [squel], complete methylation (70–100%), partial methylation (10–60%), and unmethylation, respectively. N1–N5, normal tissues; T1–T5, tumor tissues.

Fig. 5. Methylation-specific PCR analysis of the *RASSF1A* promoter in gastric carcinoma cell lines and primary tumors. Genomic DNA was extracted from 15 gastric cancer cell lines, five primary tumors (T1–T5), and adjacent noncancerous tissues (N1–N5). Bisulfite-modified DNA (50 ng) was subjected to PCR amplification of the *RASSF1A* promoter sequences using unmethylation-specific (U) and methylation-specific (M) primer sets. The PCR products (20 μl) were resolved on a 2% agarose gel.



gastric tumors, we performed methylation-specific PCR analysis for 15 cell lines and 90 primary tumors. All of nine cell lines and 39 (95.1%) of 41 primary carcinomas with loss or abnormal reduction of *RASSF1A* expression were found to be methylated, whereas none of *RASSF1A*-expressing tumors and 15 normal tissues showed methylation (Fig. 5). *Bst*UI digestion assay for the CpG island region that comprises two *Bst*UI recognition sites (CGCG) was also performed as described previously, and the identical results were obtained (data not shown). These results indicate that hypermethylation at the CpG island in the *RASSF1A* promoter is strongly associated with loss or abnormal reduction of *RASSF1A* expression.

In conclusion, our data presented here clearly demonstrate that *RASSF1*, particularly *RASSF1A*, undergoes epigenetic silencing in a considerable proportion of gastric adenocarcinomas by aberrant promoter methylation. Additionally, loss or abnormal reduction of *RASSF1A* expression showed a strong correlation with tumor stage and grade, indicating the implication of *RASSF1A* inactivation in the malignant progression of gastric cancer. Although additional studies are required to characterize the biological significance of *RASSF1* inactivation in gastric tumorigenesis, our study suggests that *RASSF1A* methylation could be a useful molecular marker for detection and prognosis of gastric cancers.

References

- Fuchs, C. S., and Mayer, R. J. Gastric carcinoma. *N. Engl. J. Med.*, 333: 32–41, 1995.
- Werner, M., Becker, K. F., Keller, G., and Hoffer, H. Gastric adenocarcinoma: pathomorphology and molecular pathology. *J. Cancer Res. Clin. Oncol.*, 127: 207–216, 2001.
- Sano, T., Tsujino, T., Yoshida, K., Nakayama, H., Haruma, K., Ito, H., Nakamura, Y., Kajiyama, G., and Tahara, E. Frequent loss of heterozygosity on chromosomes 1q, 5q, and 17p in human gastric carcinomas. *Cancer Res.*, 51: 2926–2931, 1991.
- Yustein, A. S., Harper, J. C., Petroni, G. R., Cummings, O. W., Moskaluk, C. A., and Powell, S. M. Allelotype of gastric adenocarcinoma. *Cancer Res.*, 59: 1437–1441, 1999.
- Choi, S. W., Park, S. W., Lee, K. Y., Kim, K. M., Chung, Y. J., and Rhyu, M. G. Fractional allelic loss in gastric carcinoma correlates with growth patterns. *Oncogene*, 17: 2655–2659, 1998.
- Kastury, K., Baffa, R., Druck, T., Ohta, M., Cotticelli, M. G., Inoue, H., Negrini, M., Rugge, M., Huang, D., Croce, C. M., Palazzo, J., and Huebner, K. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. *Cancer Res.*, 56: 978–983, 1996.
- Baffa, R., Veronese, M. L., Santoro, R., Mandes, B., Palazzo, J. P., Rugge, M., Santoro, E., Croce, C. M., and Huebner, K. Loss of FHIT expression in gastric carcinoma. *Cancer Res.*, 58: 4708–4714, 1998.
- Dolan, K., Garde, J., Walker, S. J., Sutton, R., Gosney, J., Field, J. K. Histological and molecular mapping of adenocarcinoma of the oesophagus and gastroesophageal junction: loss of heterozygosity occurs in histologically normal epithelium in the oesophagus and stomach. *Oncol. Rep.*, 7: 521–528, 2000.
- Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S., and Pfeifer, G. P. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. *Nat. Genet.*, 25: 315–319, 2000.
- Burbee, D. G., Forgacs, E., Zochbauer-Muller, S., Shivakumar, L., Fong, K., Gao, B., Randle, D., Kondo, M., Virmani, A., Bader, S., Sekido, Y., Latif, F., Milchgrub, S., Toyooka, S., Gazdar, A. F., Lerman, M. I., Zabarovsky, E., White, M., and Minna, J. D. Epigenetic inactivation of *RASSF1A* in lung and breast cancers and malignant phenotype suppression. *J. Natl. Cancer Inst.* (Bethesda), 93: 691–699, 2001.
- Agathangelou, A., Honorio, S., Macartney, D. P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J. A., Hosoe, S., Lerman, M. I., Minna, J. D., Maher, E. R., and Latif, F. Methylation associated inactivation of *RASSF1A* from region 3p21.3 in lung, breast and ovarian tumours. *Oncogene*, 20: 1509–1518, 2001.
- Dammann, R., Yang, G., and Pfeifer, G. P. Hypermethylation of the CpG island of Ras association domain family 1A (*RASSF1A*), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. *Cancer Res.*, 61: 3105–3109, 2001.
- Lo, K. W., Kwong, J., Hui, A. B. Y., Chan, S. Y. Y., To, K. F., Chan, A. S. C., Chow, L. S. N., Teo, P. M. L., Johnson, P. J., and Huang, D. P. High frequency of promoter hypermethylation of *RASSF1A* in nasopharyngeal carcinoma. *Cancer Res.*, 61: 3877–3881, 2001.
- Ponting, C. P., and Benjamin, D. R. A novel family of Ras-association domains. *Trends Biochem. Sci.*, 21: 422–425, 1996.
- Vavvas, D., Li, X., Avruch, J., and Zhang, X. F. Identification of Nore1 as a potential Ras effector. *J. Biol. Chem.*, 273: 5439–5442, 1998.
- Kim, S. T., Lim, D. S., Canman, C. E., and Kastan, M. B. Substrate specificities and identification of putative substrates of ATM kinase family members. *J. Biol. Chem.*, 274: 37538–37543, 1999.
- Bar-Sagi, D., and Feramisco, J. R. Microinjection of the ras oncogene protein into PC12 cells induces morphological differentiation. *Cell*, 42: 841–848, 1985.
- Mayo, M. W., Wang, C. Y., Cogswell, P. C., Rogers-Graham, K. S., Lowe, S. W., Der, C. J., and Baldwin, A. S., Jr. Requirement of NF- κ B activation to suppress p53-independent apoptosis induced by oncogenic Ras. *Science (Wash. DC)* 278: 1812–1815, 1997.
- Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J., and Clark, G. J. Ras uses the novel tumor suppressor *RASSF1* as an effector to mediate apoptosis. *J. Biol. Chem.*, 275: 35669–35672, 2000.
- Chi, S. G., deVere White, R. W., Meyers, F. J., Siders, D., Lee, F., and Gumerlock, P. H. p53 in prostate: frequent expressed transition mutations. *J. Natl. Cancer Inst.* (Bethesda), 86: 926–933, 1994.
- Chi, S. G., deVere White, R. W., Muenzer, J., and Gumerlock, P. H. Frequent alteration of CDKN2 (*p16^{INK4A}/MTS1*) expression in human primary prostate carcinomas. *Clin. Cancer Res.*, 3: 1889–1897, 1997.
- Chi, S. G., Kim, H. J., Park, B. J., Min, H. J., Park, J. H., Kim, Y. W., Dong, S. H., Kim, B. H., Lee, J. I., Chang, Y. W., Chang, R., Kim, W. K., and Yang, M. H. Mutational abrogation of the *PTEN/MMAC1* gene in gastrointestinal polyps in patients with Cowden disease. *Gastroenterology*, 115: 1084–1089, 1998.
- Kang, M. J., Park, B. J., Byun, D. S., Park, J. I., Kim, H. J., Park, J. H., and Chi, S. G. Loss of imprinting and elevated expression of wild type p73 in human gastric adenocarcinoma. *Clin. Cancer Res.*, 6: 1767–1771, 2000.
- Wistuba, I. I., Behrens, C., Virmani, A. K., Mele, G., Milchgrub, S., Girard, L., Fondon, J. W., III, Garner, H. R., McKay, B., Latif, F., Lerman, M. I., Lam, S., Gazdar, A. F., and Minna, J. D. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints. *Cancer Res.*, 60: 1949–1960, 2000.
- Sekido, Y., Ahmadian, M., Wistuba, I. I., Latif, F., Bader, S., Wei, M. H., Duh, F. M., Gazdar, A. F., Lerman, M. I., and Minna, J. D. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. *Oncogene*, 16: 3151–3157, 1998.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Frequent Epigenetic Inactivation of *RASSF1A* by Aberrant Promoter Hypermethylation in Human Gastric Adenocarcinoma

Do-Sun Byun, Min-Goo Lee, Kwon-Seok Chae, et al.

Cancer Res 2001;61:7034-7038.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/61/19/7034>

Cited articles This article cites 25 articles, 13 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/61/19/7034.full#ref-list-1>

Citing articles This article has been cited by 14 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/61/19/7034.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/61/19/7034>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.